CADL
Candel Therapeutics Inc
NASDAQ · Biotechnology
$5.83
+0.54 (+10.21%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 45.25M | 41.90M | 41.45M |
| Net Income | -4,564,062 | -5,052,559 | -4,078,464 |
| EPS | — | — | — |
| Profit Margin | -10.1% | -12.1% | -9.8% |
| Rev Growth | -8.7% | -6.2% | +3.8% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 147.03M | 131.85M | 164.02M |
| Total Equity | 175.21M | 170.29M | 145.89M |
| D/E Ratio | 0.84 | 0.77 | 1.12 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | -6,328,796 | -6,835,485 | -6,691,447 |
| Free Cash Flow | -4,822,512 | -5,572,664 | -3,889,078 |